Drug
Flu Igiv
Flu Igiv: highest development phase Phase 2, developed by Emergent BioSolutions. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| FLU-IGIV NCT03315104 | Phase 2 | Influenza A H3N2 |
Latest
No recent events.
Follow Flu Igiv on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.